Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, December 8, 2021
[ Wed, Dec 08th 2021
] - WOPRAI
[ Wed, Dec 08th 2021
] - WOPRAI
[ Wed, Dec 08th 2021
] - WOPRAI
[ Wed, Dec 08th 2021
] - WOPRAI
[ Wed, Dec 08th 2021
] - WOPRAI
Tue, December 7, 2021
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
[ Tue, Dec 07th 2021
] - WOPRAI
Vamil Divan Maintained (ACAD) at Hold with Increased Target to $26 on, Dec 7th, 2021
Vamil Divan of Mizuho, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $24 to $26 on, Dec 7th, 2021.
Vamil has made no other calls on ACAD in the last 4 months.
There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Vamil's Rating of Hold.
This is the rating of the analyst that currently disagrees with Vamil
- Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $23 on, Monday, November 1st, 2021
